- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
AcrySof toric IOL offers spectacle independence
The AcrySof toric intraocular lens (IOL) (Alcon) offers greater spectacle independence than the monofocal AcrySof SA60AT single-piece IOL (Alcon).
The AcrySof toric intraocular lens (IOL) (Alcon) offers greater spectacle independence than the monofocal AcrySof SA60AT single-piece IOL (Alcon), according to Paul Ernest from Jackson, USA.
Dr Ernest enrolled 480 patients and randomized them to receive either the control lens, AcrySof SA60AT single piece IOL (n=237), or the AcrySof toric IOL (n=243). Each patient had at least 0.75 D of regular astigmatism and age-related cataracts in one or both eyes.
The toric IOL patients reported a significantly greater rate of spectacle independence than controls (p<0.0001). Compared with controls, the percentage of toric patients achieving an uncorrected distance visual acuity (UDCVA) of 20/20 or better (19.4% versus 40.7%, respectively) or 20/25 or better (41.4% versus 63.7%, respectively) was significant (p<0.0001).
The comparison of the lenses demonstrates that the AcrySof toric IOL offers a much greater level of spectacle independence than its monofocal counterpart.
